AUPH vs. CRNX

Last updated Apr 2, 2026

Compare and contrast key facts about Aurinia Pharmaceuticals Inc. (AUPH) and Crinetics Pharmaceuticals, Inc. (CRNX).

Performance

AUPH vs. CRNX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aurinia Pharmaceuticals Inc. (AUPH) and Crinetics Pharmaceuticals, Inc. (CRNX). The values are adjusted to include any dividend payments, if applicable.

AUPH vs. CRNX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
AUPH Aurinia Pharmaceuticals Inc.	-3.01%	77.62%	-0.11%	108.10%	-81.11%	65.37%	-31.74%	197.07%	19.65%
CRNX Crinetics Pharmaceuticals, Inc.	-21.44%	-8.96%	43.70%	94.43%	-35.59%	101.35%	-43.76%	-16.34%	22.36%

Fundamentals

Market Cap AUPH : $2.15B CRNX : $3.44B
EPS AUPH : $2.06 CRNX : -$4.95
PS Ratio AUPH : 7.61 CRNX : 634.38
PB Ratio AUPH : 3.69 CRNX : 3.47
Total Revenue (TTM) AUPH : $283.06M CRNX : $5.42M
Gross Profit (TTM) AUPH : $250.39M CRNX : $5.88M
EBITDA (TTM) AUPH : $109.83M CRNX : -$513.87M

Returns By Period

In the year-to-date period, AUPH achieves a -3.01% return, which is significantly higher than CRNX's -21.44% return.

AUPH

• 1D: 4.39%
• 1M: 8.87%
• YTD: -3.01%
• 6M: 35.70%
• 1Y: 92.17%
• 3Y*: 12.17%
• 5Y*: 3.32%
• 10Y*: 18.02%

CRNX

• 1D: 0.69%
• 1M: -10.10%
• YTD: -21.44%
• 6M: -12.11%
• 1Y: 19.43%
• 3Y*: 31.56%
• 5Y*: 17.98%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AUPH vs. CRNX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUPH

AUPH Risk / Return Rank: 91
AUPH Sharpe Ratio Rank: 90
AUPH Sortino Ratio Rank: 88
AUPH Omega Ratio Rank: 88
AUPH Calmar Ratio Rank: 95
AUPH Martin Ratio Rank: 92

CRNX

CRNX Risk / Return Rank: 50
CRNX Sharpe Ratio Rank: 53
CRNX Sortino Ratio Rank: 54
CRNX Omega Ratio Rank: 51
CRNX Calmar Ratio Rank: 46
CRNX Martin Ratio Rank: 47

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AUPH vs. CRNX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and Crinetics Pharmaceuticals, Inc. (CRNX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AUPH	CRNX	Difference
Sharpe ratio Return per unit of total volatility	2.04	0.33	+1.71
Sortino ratio Return per unit of downside risk	2.66	1.00	+1.67
Omega ratio Gain probability vs. loss probability	1.38	1.11	+0.26
Calmar ratio Return relative to maximum drawdown	5.81	0.22	+5.59
Martin ratio Return relative to average drawdown	12.66	0.64	+12.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AUPH vs. CRNX - Sharpe Ratio Comparison

The current AUPH Sharpe Ratio is 2.04, which is higher than the CRNX Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of AUPH and CRNX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AUPH	CRNX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.04	0.33	+1.71
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.05	0.28	-0.23
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.24	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.17	0.08	+0.09

Correlation

The correlation between AUPH and CRNX is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AUPH vs. CRNX - Dividend Comparison

Neither AUPH nor CRNX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AUPH vs. CRNX - Drawdown Comparison

The maximum AUPH drawdown since its inception was -87.58%, which is greater than CRNX's maximum drawdown of -68.70%. Use the drawdown chart below to compare losses from any high point for AUPH and CRNX.

Drawdown Indicators

	AUPH	CRNX	Difference
Max Drawdown Largest peak-to-trough decline	-87.58%	-68.70%	-18.88%
Max Drawdown (1Y) Largest decline over 1 year	-15.91%	-40.33%	+24.42%
Max Drawdown (5Y) Largest decline over 5 years	-87.58%	-57.88%	-29.70%
Max Drawdown (10Y) Largest decline over 10 years	-87.58%	—	—
Current Drawdown Current decline from peak	-53.23%	-39.74%	-13.49%
Average Drawdown Average peak-to-trough decline	-49.17%	-37.32%	-11.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.30%	14.05%	-6.75%

Volatility

AUPH vs. CRNX - Volatility Comparison

Aurinia Pharmaceuticals Inc. (AUPH) and Crinetics Pharmaceuticals, Inc. (CRNX) have volatilities of 13.51% and 13.73%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AUPH	CRNX	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.51%	13.73%	-0.22%
Volatility (6M) Calculated over the trailing 6-month period	26.87%	34.83%	-7.96%
Volatility (1Y) Calculated over the trailing 1-year period	45.40%	59.15%	-13.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.71%	63.99%	+4.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.42%	65.36%	+9.06%

Financials